Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)

To access the efficacy of intravenous (IV) administration of CD-NP on changes in cardiac output and wedge pressure in patients with stabilized acute heart failure

Key Inclusion Criteria:

• Hospitalization for AHF
• In need of hemodynamic monitoring

Key Exclusion Criteria:

• Administration of intravenous radiographic contrast agent within 7 days prior to screening or planned IV contrast media administration in the 4 days after screening or acute contrast-induced nephropathy at the time of screening
• Current or planned treatment with any IV therapies, including diuretics, vasodilators (including nesiritide), vasopressin antagonists, positive inotropic agents and vasopressors, or mechanical support
• Current or planned ultrafiltration, hemofiltration, or dialysis within 7 days of screening
• Significant pulmonary disease
• Known valvular heart disease
• Any organ transplant recipient or patient currently listed for transplant or admitted for any transplantation.
• Major surgery within 30 days of screening
• Other major disability or disease with expected survival less than 6 months.
• Major neurologic event, including cerebrovascular events, in the 60 days prior to screening
• Clinical diagnosis of acute coronary syndrome within 45 days of screening
• Troponin T ≥ 3 times the upper limit of normal at screening
• Significant arrhythmias
• Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy
• Liver function abnormality
• Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days prior to screening